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Abstract  27 
Objectives: The A1470T polymorphism (rs1049434) in the monocarboxylate (lactate/pyruvate) transporter 1 28 
gene (MCT1) has been suggested to influence athletic performance in the general population. We compared 29 
genotype distributions and allele frequencies of the MCT1 gene A1470T polymorphism between endurance 30 
athletes, sprint/power athletes and matched controls. We also examined the association between the MCT1 31 
A1470T and the athletes’ competition level (‘elite’ and ‘national’ level).  32 
Design: The study involved endurance athletes (n=112), sprint/power athletes (n=100), and unrelated 33 
sedentary controls (n=621), all Caucasians.  34 
Method: Genomic DNA was extracted from buccal epithelium using a standard protocol. We conducted 35 
Fisher’s exact tests and multinomial logistic regression analyses to assess the association between MCT1 36 
genotype and athletic status/competition level.  37 
Results: Sprint/power athletes were more likely than controls to possess the minor T allele (TT genotype 38 
compared to the AA [p < 0.001]; TT or AT compared to the AA [p = 0.007]; TT compared to both AA or AT 39 
genotypes [p < 0.001]). Likewise, sprint/power athletes were more likely than endurance athletes to have the 40 
TT genotype compared to the AA (p = 0.029) and the TT compared to both AA or AT genotypes (p = 0.027). 41 
Furthermore, elite sprint/power athletes were more likely than national-level athletes to have the TT genotype 42 
compared to the AA (p=0.044), and more likely to have the TT genotype compared to both AA or AT 43 
genotypes (recessive model) (p=0.045). 44 
Conclusions: the MCT1 TT genotype is associated with elite sprint/power athletic status. Future studies are 45 
encouraged to replicate these findings in other elite athlete cohorts. 46 
 47 
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transport protein 1 49 
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i. Introduction 52 
 Along with environmental factors, elite athletic performance is also influenced by genetic factors.1  53 
Family and twin studies have demonstrated that genetics play a significant role in athletic performance.  A 54 
genome-wide linkage scan for athletic status reported a heritability of ~ 66% for athletic status in 700 British 55 
female dizygotic twin pairs.2 In the HEalth, RIsk factors, exercise Training And Genetics (HERITAGE) 56 
family study, the reported heritability of changes in maximal oxygen uptake (VO2 max) with exercise training 57 
was ~47% in sedentary subjects.3  In another study, the heritability of explosive strength, which is an 58 
important predictor of sprint performance, was assessed at 74-84%.4 To date, more than 20 Single Nucleotide 59 
Polymorphisms (SNPs) have been reported to be associated with elite athletic performance.1, 5 Thus far, only 60 
the ACTN3 R577X polymorphism6-8  has shown consistent association with elite athletic performance across 61 
multiple cohorts,9-11 while the ACE I/D is another highly studied SNP with respect to elite athletic 62 
performance providing less consistent results.12, 13 However, the monocarboxylate (lactate/pyruvate) 63 
transporter (MCT) family has not previously been researched in relation to elite athletic performance and thus 64 
presents interesting and novel candidate genes for investigation. 65 
During high-intensity exercise, lactate and protons accumulate in the contracting muscles as a result of 66 
glycolysis. In order to maintain glycolysis, lactate is transported out of the cell at high rates by 67 
monocarboxylate transporters (MCTs).14-16 The MCT family currently comprises 14 members. In skeletal 68 
muscle, the most important and well-described isoforms are MCT1 and MCT4.16 These two MCTs mediate 69 
the 1:1 transmembrane cotransport of lactate and protons, relative to the lactate concentration and proton 70 
gradient, either into or out of skeletal muscle. Without the MCTs, lactate could not be as rapidly exchanged 71 
between tissue compartments. MCT4 has not been correlated with fibre type, while MCT1 is more 72 
prevalence in Type I oxidative muscle fibres.17 It has been suggested that a key physiological role of MCT1 73 
is to take up lactate from the circulation, while MCT4 seems better suited to assist the extrusion of lactate 74 
from glycolytic fibres.15 The MCT1 gene (official symbol SLC16A1; location: 1p12) may be therefore 75 
potentially related to elite athletic performance. 76 
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 MCT1 has been found predominantly in type I, oxidative muscle fibres, and only in small amounts in type 77 
IIX, glycolytic muscle fibres.16, 18 Chronic muscle inactivity has been shown to reduce MCT1 gene 78 
expression19, whereas chronic electrical muscle stimulations (which mimics exercise) increase MCT1 gene 79 
expression in rats.20 Furthermore, in human skeletal muscle MCT1 protein expression level remains elevated 80 
following both continuous-single intensity21 and high-intensity interval endurance training18, 21, leading to 81 
increased membrane transporter density.22  82 
 A common A1470T (Glu490Asp) polymorphism (rs1049434) that leads to the replacement of glutamic 83 
acid with aspartic acid has been identified in the MCT1 gene.23 Carriers of the minor T allele have 60-65% 84 
reduced lactate transport rates23 and experience higher blood lactate accumulations during high intensity 85 
circuit weight training, compared to carriers of the A allele.24 These findings suggest that the MCT1 T allele 86 
may impede endurance performance and contribute to individual differences in response to exercise training.  87 
 Genetic research in sport is still in its infancy and this study is designed to further explore the importance 88 
of genes in various athlete phenotypes and competition levels. The aim of this study was to compare 89 
genotype distributions and allele frequencies of the MCT1 gene A1470T polymorphism between elite 90 
endurance athletes, elite sprint/power athletes and matched controls. In light of the relationship observed 91 
between blood lactate accumulation and MCT1 T allele, we hypothesised that MCT1 A1470T polymorphism 92 
would be associated with elite athletic status. To our knowledge, this is the first study to investigate the 93 
MCT1 gene and elite athletic performance; thus, codominant, dominant and recessive genetic models were 94 
assessed to determine differences amongst athlete phenotype (endurance, sprint/power, control). We also 95 
examined the association between the MCT1 A1470T polymorphism and the athletes’ competition level 96 
(‘elite’ and ‘national’ level) for both athlete groups.  97 
 98 
ii. Methods 99 
 The study was approved by the Pomeranian Medical University Ethics Committee, Poland, and written 100 
informed consent was obtained from each participant. The study involved 212 Polish athletes (164 males and 101 
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48 females; mean age ± SD, 27.8 ± 7.1 yr; range = 16- 41) and 621 unrelated sedentary volunteers (students 102 
of University of Szczecin, 453 males and 168 females; mean age ± SD, 20.7 ± 0.9 yr; range = 19-23 yrs). The 103 
athletes and controls were all European Caucasians.  104 
The athletes were categorized as either endurance athletes or sprint/power athletes as determined by the 105 
distance, duration and energy requirements of their event/ sport.  All athletes were ranked in the top 10 106 
nationally in their sport discipline and grouped as being either ‘elite-level’ or ‘national-level’ based on their 107 
best personal performance. Those in the elite group had participated in international competitions such as 108 
World and European Championships, and/or Olympic Games, whereas those in the national-level group had 109 
participated in national competitions only.  110 
 The endurance athlete group (n=112, 84% males) included athletes competing in long distance/ duration 111 
events demanding predominantly aerobic energy production. This group included 15-50 km cross-country 112 
skiers (n= 2), race walkers (n= 6), road cyclists (n= 14), triathletes (n= 4), 5-10 km runners (n = 17), 400-113 
1500 m swimmers (n= 11),  rowers (n= 42), 1500 m runners (n= 7) and kayakers (n= 9). In this group, 66 114 
(59%) were elite athletes. 115 
The sprint/ power group (n=100, 70% males) included sprint and power athletes whose events demand 116 
predominantly anaerobic energy production. Athletes in this group included: 100-400 m runners (n = 29), 117 
jumpers (n= 15), power lifters (n= 22), throwers (n= 14) and weightlifters (n= 20). In this group, 61 (61%) 118 
were elite athletes. 119 
Detailed methods of sample collection, genotyping, and data analysis are outlined below, according to 120 
recent recommendations for reporting of genotype-phenotype association studies.25  Samples were collected 121 
during the years 2008-2012. Various methods were used to obtain the samples, including: targeting national 122 
teams and providing information to national coaching staff and athletes attending training camps.  123 
The buccal cells donated by the subjects were collected in Resuspension Solution (Sigma-Aldrich, USA) 124 
with use of Sterile Foam Tipped Applicators (Puritan, USA). DNA was extracted from the buccal cells using 125 
GenElute Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich, USA) according to the producer 126 
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protocol. All DNA samples were then stored in the same conditions at -25oC until subsequent processes were 127 
performed.  128 
The 187 bp fragment of MCT1 gene was amplified by polymerase chain reaction (PCR) using 129 
Mastercycler (Eppendorf, Germany). The PCR reactions were performed in 10 μl volumes with 1× PCR 130 
buffer, 1.75 mM MgCl2, 1 μM of each deoxynucleotide triphosphate (dNTP, Novazyme, Poland), 4 131 
picomoles of each forward primer 5'-AGCAAACGAGCAGAAAAAGG-3' and reverse primer 5'-132 
CTGGGTCATGAACTGCTCAA-3' (Genomed, Poland), as well as 0.5 U Taq Polymerase (Novazyme, 133 
Poland) and 30-50 ng of template DNA. The primers used in the study were previously described and 134 
validated by Fedotovskaya et al.19 PCR was performed as follows: 60 seconds of initial denaturation at 94oC, 135 
followed by 35 cycles (each cycle consisted of 20 second of denaturation at 94oC, 20 second of annealing at 136 
65oC, and 30 second of extension at 72oC) and 90 second of final elongation at 72oC. 137 
The amplified PCR fragments were subsequently digested with BccI restriction endonuclease (New England 138 
Biolabs, USA). This method yields 83 bp and 104 bp fragments in the presence of the T allele and an 139 
undigested 187 bp fragment in the presence of the A allele. Digested products were then electrophoretically 140 
separated in ethidium bromide-stained 5% high resolution agarose (Sigma-Aldrich, USA) gels and viewed by 141 
UV trans illumination. We performed genotyping exclusively at the Molecular Laboratory at Gdansk 142 
University of Physical Education and Sport, Poland, with all samples genotyped in duplicate. 143 
Chi squared tests were used to test for the presence of Hardy-Weinberg equilibrium (HWE). Genotype 144 
frequencies were compared according to athletic status (i.e. controls, endurance, or sprint/power athlete) 145 
using Fisher’s exact test. Multinomial logistic regression analyses were conducted to assess the association 146 
between genotype and athletic status/competition level. Sex was adjusted for in the first stage of analysis as 147 
there were sex distribution differences in each athletic status groups and the control group. As the T allele 148 
was considered to be the risk allele, analyses were made comparing AA (reference group) vs. AT vs. TT 149 
(codominant model); AA (reference group) vs. TT and TA combined (dominant model); AA and TA 150 
combined (reference group) vs. TT (recessive model). Significance between these planned comparisons was 151 
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accepted when p ≤ 0.05. Odds ratios with 95% confidence intervals were also calculated for estimation of the 152 
risk effect.  153 
 154 
iii. Results 155 
 Genotypes were determined for 212 DNA samples of athletes and 621 DNA samples of controls – 98% 156 
of genotypes could be called. 157 
 Genotype and allele frequency distributions amongst all participants are presented in Table 1. Genotype 158 
distributions of all groups met HWE (all p > 0.10). Table 1 outlines the associations between genotypes and 159 
athletic status. All analyses included an adjustment for sex, however, sex was not a significant variable for 160 
any association. After adjusting for sex, sprint/power athletes were more likely than controls to possess the 161 
minor T allele (TT genotype compared to the AA [OR = 3.40; CI = 1.88 – 6.15; p < 0.001]; TT or AT 162 
compared to the AA [OR = 1.92; CI = 1.2 – 3.07; p = 0.007]; TT compared to both AA or AT genotypes [OR 163 
= 2.67; CI = 1.61 – 4.40; p < 0.001]). Sprint/power athletes were also more likely than endurance athletes to 164 
possess the minor T allele, with a greater likelihood of having the TT genotype compared to the AA (OR = 165 
2.44; CI = 1.10-5.41; p = 0.029) and the TT compared to AA+AT genotypes (OR = 2.20; CI = 1.10-4.43; p = 166 
0.027). These results indicate that the T allele  may be beneficial for sprint/ power athletes compared to 167 
endurance, although the risk appears to be only present in the homozygous form indicating a recessive effect. 168 
 Sprint/power athletes also indicated differences between competition levels (Table 2). Elite athletes were 169 
more likely than national-level athletes to have the TT genotype compared to the AA (OR = 3.41; CI = 1.04 – 170 
11.2; p=0.044), and also, the TT genotype compared to the AA +AT genotypes combined (OR = 2.84; CI = 171 
1.02 – 7.91; p = 0.045) suggesting a recessive effect here as well. The significant increase in likelihood of 172 
elite status observed in the sprint/power athletes was, however, not observed in endurance athletes (all 173 
comparisons p > 0.05). The effect of the T allele on elite status thus appears to be specific to sprint/power 174 
athletes alone. Thus, at both elite and national levels the recessive T allele appears to be associated with 175 
sprint/ power athletes, but inconsequential for endurance athletes. 176 
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iv. Discussion   177 
Sprint/power performance is influenced by genetics1, 26 and several genetic variants have been associated 178 
with elite sprint/power performance, including the ACE I/D, ACTN3 R577X, AGT Met235Thr, NOS3 -786 179 
T/C, IL6 -174 G/C, and GDF-8 K153R.27 However, some of these variants provide no consistent association 180 
with sprint/power performance (i.e. ACE I/D) or require additional testing in multiple cohorts (e.g. IL6, 181 
AMPD1, NOS3). Furthermore, none of the abovementioned variants are related to lactate transport, an 182 
important factor in athletic performance. According to our hypothesis, we found, for the first time, that the 183 
MCT1 T allele is associated with sprint/ power performance in a recessive genetic model and the TT 184 
genotype was more prevalent in sprint/power athletes compared to both controls (OR = 2.67; CI = 1.61 – 185 
4.40; p < 0.001) and endurance athletes (OR = 2.20; CI = 1.10-4.43; p = 0.027). This finding reinforces the 186 
hypothesis that MCT1 A1470T might be one, of what appears to be many, polymorphisms that influence 187 
athletic performance.  188 
There is also biochemical evidence to suggest that MCT1 A1470T polymorphism is associated with 189 
exercise performance in humans.  A 2010 pilot study in high intensity circuit training by Cuperio et al.24 190 
investigated the influence of MCT1 A1470T polymorphism on lactate accumulation after high intensity 191 
circuit training. In this study the carriers of the MCT1 AT or TT genotype seem to exhibit a decreased lactate 192 
transport capability into the less active muscle cells for oxidation. The Cuperio et al. study24, however, did 193 
not provide any insight into the mechanism behind the association between MCT1 and athletic performance. 194 
We suggest that this association may be directly related to the increased accumulation of lactate within the 195 
blood, triggering muscle fatigue and limited aerobic performance, explaining why the MCT1 T allele was 196 
significantly more prevalent in anaerobic (sprint/power) athletes in our findings. We suggest that this 197 
association may be directly related to the increased accumulation of lactate within the blood triggering 198 
muscle fatigue and limiting aerobic performance. Alternatively, high lactate levels may induce the expression 199 
of muscle hypertrophy associated genes (i.e. those encoding mTOR, IGF-1, growth hormone etc.), as 200 
increased lactate levels have been found to be associated with endogenous anabolic factors and/or muscle 201 
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hypertrophy.21 Consequently, high levels of lactate in skeletal muscles may assist elite athletes to increase 202 
muscle mass and strength enhancing their sprint/power performance. We believe that a functional aproach to 203 
uncover the direct influence of MCT1 A1470T polymorphism on athletic performance should be embraced in 204 
future studies. 205 
An additional novel finding in the present study is that the likelihood of having the MCT1 TT genotype is 206 
2.8 times higher for an elite-level sprint/power athlete compared with national-level counterparts. To date, 207 
only the ACTN3 R577X has been associated with either sprint8, 28 or endurance8 performance with respect to 208 
the level of athletic performance. This observation indicates that while the MCT1 recessive model might be 209 
important in the development of sprint/power ability, it is even more important in the development of ‘elite’ 210 
sprint/power performance. This information may assist coaches and exercise physiologist to further optimise  211 
training loads, not only based on environmental factors, but also based on their genomic factors. It is worthy 212 
to note that this genotype was not related to the performance amongst endurance athletes, and further research 213 
is needed to clearly identify genotypes that are associated with elite the level of endurance performances. 214 
In order to confirm the results observed in this report, functional studies related to the the effect of MCT1 215 
alleles on skeletal muscle hypertrophy and alterations in sprint/power performance are needed. Future 216 
research may also benefit from featuring the competition level of athletes (elite/national level) as a more 217 
prominent variable in analesys and that athletes have peaked in their career to ensure the cross-section of 218 
results is representative of the athletes’ highest performance ability.  219 
Despite advances in our understanding of the genetic basis of power and sprint performance, there are 220 
limitations that have hampered the progression of genetic based athletic research which need to be addressed. 221 
The primary limiting factor in genetic association studies is the need to recruit large groups of elite athletes to 222 
overcome the obvious barrier of large sample size for detecting genetic associations. Recently, it was 223 
estimated that, testing a single polymorphism using a case-control design (athletes vs. non-athletes) would 224 
require ~250 cases to obtain a statistical power of 80%.28. To address this, large multi-site collaborations, and 225 
data sharing between researchers, will be necessary to ensure sufficient statistical power is obtained. 226 
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Additionally, we recognise that the current paper focuses on one genetic variant whereas elite athletic 227 
performance is highly polygenic trait, 29, 30 and it is therefore very likely that more novel variants will be 228 
discovered that influence sprint/power performance. That said, the identification of MCT1 A1470T as a 229 
genetic variant associated with sprint/power performance presents a novel and intriguing candidate gene for 230 
further analysis in relation to athletic sprint /power phenotypes.  231 
v. Conclusion 232 
In conclusion, we provide evidence for an association between MCT1 A1470T polymorphism and elite 233 
sprint/ power status in a group of elite European athletes. The findings indicated that the MCT1 TT genotype 234 
was overrepresented in sprint/power athletes compared to both endurance athletes and non-athlete controls, 235 
which were not significantly different to each other. Furthermore, within the sprint/power athletes, the TT 236 
genotype was overrepresented in elite level athletes compared to national level athletes.  These findings 237 
provide support for the potential influential role of the MCT1 A1470T polymorphism in determining elite 238 
athletic status. Future studies are encouraged to replicate these findings by recruiting large enough samples of 239 
elite athletes. More research is also required to understand the mechanisms involved in this observed 240 
relationship between the MCT1 A1470T polymorphism and athlete phenotype. 241 
 242 
vi. Practical implications 243 
• MCT1 A1470T polymorphism should be considered as one of the polymorphisms that may influence 244 
sprint/power performance. 245 
• The MCT1 A1470T polymorphism is over-represented in elite sprint/power athletes compared to 246 
national level athletes.  247 
• Discovering the complex relationship between gene variants and sprint/power performance may 248 
assist coaches to optimize training. 249 
 250 
 251 
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viii. Tables 
Table 1. Genotype frequencies and odds ratios/CI for each genetic model in each athlete phenotype 
 
Genetic 
model 
Control Endurance Sprint/ Power Endurance vs Control Sprint/Power vs Control 
Sprint/Power vs 
Endurance 
n (%) n (%) n (%) OR 95% CI p OR 95% CI p OR 95% CI p 
Codominant             
 AA 258 (41.5%) 40 (36%) 27 (27%) 1.00 Referent  1.00 Referent  1.00 Referent  
 AT 285 (45.9%) 56 (50%) 46 (46%) 1.28 0.82-1.98 0.280 1.53 0.92-2.53 0.102 1.18 0.63- 2.23 0.604 
 TT 78 (12.6%) 16 (14%) 27 (27%) 1.24 0.66-2.34 0.506 3.40 1.88-6.15 <0.001* 2.44 1.10- 5.41 0.029* 
Dominant             
 AA 258 (41.5%) 40 (36%) 27 (27%) 1.00 Referent  1.00 Referent  1.00 Referent  
 AT+TT 363 (58.5%) 72 (64%) 73 (73%) 1.27 0.83-1.93 0.268 1.92 1.20-3.07 0.007* 1.46 0.81- 2.65 0.211 
Recessive             
 AA+AT 543 (87%) 96 (86%) 73 (73%) 1.00 Referent  1.00 Referent  1.00 Referent  
 TT 78 (12.5%) 16 (14%) 27 (27%) 1.08 0.61-1.94 0.785 2.67 1.61-4.43 <0.001* 2.20 1.10- 4.43 0.027* 
* Significant at the α = 0.05 level. 
Table 2. Genotype frequencies and odds ratios/CI for each genetic model in each athlete phenotype and competition level 1 
 2 
Genetic 
model 
Endurance  Sprint/Power 
Elite National OR 95% CI  Elite National OR 95% CI 
Codominant          
 AA 22 (33.3%) 18 (39.1%) 1.00 Referent  14 (23.0%) 13 (33.3%) 1.00 Referent 
 AT 37 (56.1%) 19 (41.3%) 1.63 0.71-3.78  26 (42.6%) 20 (51.3%) 1.34 0.50-3.56 
 TT  7 (10.6%)  9 (19.5%) 0.63 0.20-2.02  21 (34.4%)  6 (15.4%) 3.41 1.04-11.2* 
Dominant          
 AA 22 (33.3%) 18 (39.1%) 1.00 Referent  14 (23.0%) 13 (33.3%) 1.00 Referent 
 AT+TT 44 (66.7%) 28 (60.9%) 1.30 0.59-2.84  47 (77%) 26 (66.7%) 1.88 0.74-4.62 
Recessive          
 AA+AT 59 (89.4%) 37 (80.5%) 1.00 Referent  40 (65.6%) 33 (84.6%) 1.00 Referent 
 TT   7 (10.6%)   9 (19.5%) 0.48 0.16-1.40  21 (34.4%)  6 (15.4%) 2.84 1.02-7.90* 
* Significant at the α = 0.05 level.  3 
